Day 4 Program

Poster Spotlight 10: Translational Insights into CDK4/6 Inhibitor Resistance and Novel Therapeutic Strategies 

Day 4: December 11, 2026

7:00 AM–8:30 AM CST

301 ABC

Session Details

Moderator

Seth A Wander, Mass General Cancer Center, Boston, MA

PS10-1

Circulating tumor DNA to inform timing of CDK4/6 inhibitor treatment and to understand treatment failure in estrogen receptor-positive/HER2 negative advanced breast cancer – results from the SONIA trial

John WM Martens, Erasmus MC Cancer institute, Rotterdam, Netherlands

PS10-2

Tumor subtype conversion after first-line endocrine therapy plus CDK4/6 inhibitor progression in patients with Hormone Receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- aBC): results from the multicenter, real-world Italian study PALMARES-2

Leonardo Provenzano, IFOM ETS, AIRC Institute of Molecular Oncology, Milan, Italy

PS10-3

Distinct molecular mechanisms between early and late resistance to palbociclib with endocrine therapy in HR+/HER2− metastatic breast cancer

Hee Kyung Ahn, Samsung Medical Center, Seoul, Korea, Republic of

PS10-4

Ribociclib versus palbociclib in HER2-enriched HR+/HER2− metastatic breast cancer: results from the randomized HARMONIA (SOLTI-2101/AFT-58) phase III trial

Tomás Pascual, Hospital Clínic de Barcelona // August Pi i Sunyer Biomedical Research Institute // SOLTI, Barcelona, Spain

PS10-5

Evolving Translational Approaches to Model 1st Generation CDK4/6 Inhibitor Resistance

Julie Nangia

PS10-6

Phase I/II Trial of INX-315, an oral selective CDK2 inhibitor, in combination with abemaciclib and fulvestrant after progression on a CDK4/6 inhibitor and endocrine therapy in HR+/HER2-negative metastatic breast cancer

Antoinette R Tan, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC

PS10-7

The Wnt pathway is a targetable vulnerability of drug-tolerant persister cells surviving CDK4/6 inhibitor treatment

Yuki Matsunaga, UT Southwestern Medical Center, Dallas, TX

PS10-8

Transcriptional profiling of tumor biopsies in neoadjuvant FourLight-2, a randomized phase 2 window-of-opportunity study, evaluating atirmociclib plus letrozole versus letrozole alone in HR+/HER2− breast cancer

Shom Goel, Peter MacCallum Cancer Centre, Melbourne Victoria, Australia

PS10-9

Znf703 within the 8p11-12 amplicon drives antiestrogen and cdk4/6 inhibitor resistance in estrogen receptor positive breast cancer

Doohyung Lee, UT Southwestern Medical Center, Dallas, TX

PS10-10

Culmerciclib plus fulvestrant versus placebo plus fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer: prespecified final analysis of the phase 3 CULMINATE-2 trial

Erwei Song, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

PS10-11

Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer

Nancy U. Lin, Dana Farber Cancer Institute, Boston, MA

PS10-12

Beyond CDK4/6: New Resistance Mechanisms and Emerging CDK4 and CDK2 Inhibitors

Anton Safonov, Memorial Sloan Kettering Cancer Center, New York, NY